Rockwell Medical (NASDAQ:RMTI) Announces Earnings Results

Rockwell Medical (NASDAQ:RMTI) posted its quarterly earnings results on Tuesday. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.05, MarketWatch Earnings reports. Rockwell Medical had a negative return on equity of 88.74% and a negative net margin of 15.32%. During the same period in the previous year, the firm earned ($0.40) earnings per share.

Rockwell Medical Trading Up 3.1 %

NASDAQ:RMTI opened at $2.02 on Wednesday. The stock has a fifty day moving average price of $1.96 and a 200 day moving average price of $2.94. The company has a current ratio of 1.58, a quick ratio of 1.25 and a debt-to-equity ratio of 0.69. Rockwell Medical has a 12-month low of $0.94 and a 12-month high of $6.24. The firm has a market cap of $57.55 million, a PE ratio of -2.23 and a beta of 1.46.

Institutional Investors Weigh In On Rockwell Medical

A number of hedge funds have recently bought and sold shares of RMTI. Osaic Holdings Inc. increased its stake in shares of Rockwell Medical by 205.4% during the second quarter. Osaic Holdings Inc. now owns 7,583 shares of the company’s stock worth $42,000 after buying an additional 5,100 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Rockwell Medical by 112.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,284 shares of the company’s stock valued at $56,000 after purchasing an additional 5,447 shares during the last quarter. Cetera Advisor Networks LLC purchased a new stake in shares of Rockwell Medical in the 2nd quarter valued at approximately $77,000. Marshall Wace LLP purchased a new stake in shares of Rockwell Medical during the 2nd quarter worth $88,000. Finally, State Street Corp grew its stake in shares of Rockwell Medical by 94.2% during the first quarter. State Street Corp now owns 33,604 shares of the company’s stock worth $61,000 after purchasing an additional 16,300 shares in the last quarter. Institutional investors and hedge funds own 22.07% of the company’s stock.

Wall Street Analyst Weigh In

RMTI has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Rockwell Medical in a research report on Wednesday, October 4th. StockNews.com cut Rockwell Medical from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Maxim Group initiated coverage on Rockwell Medical in a research note on Thursday, October 5th. They issued a “buy” rating and a $5.00 price target on the stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in patients undergoing hemodialysis.